My Treatment Approach: Improving Chronic Lymphocytic Leukemia Management and Treatment Outcomes : Episode 3

Opinion

Video

July 2, 2024

Navigating Continuous BTKi Therapy for CLL in the 1L Setting

Author(s):

Catherine C. Coombs, MD,Bita Fakhri, MD, MPH

John N. Allan, MD, describes how he selects patients for first-line treatment with continuous BTK inhibitor therapy, referencing data from the RESONATE-2, ELEVATE-TN, and SEQUOIA studies.

EP: 1.Patient with Newly Diagnosed CLL with High-Risk Features

EP: 2.Expert Perspectives on 1L Treatment Approaches in Newly Diagnosed CLL

Now Viewing

EP: 3.Navigating Continuous BTKi Therapy for CLL in the 1L Setting

EP: 4.Implications of Real-World Data in the 1L Treatment of High-Risk CLL

EP: 5.Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL

EP: 6.Considerations for 1L Doublet and Triplet Therapy with Venetoclax in CLL

EP: 7.Perspectives on Shared Decision-Making in the Treatment of CLL

EP: 8.Strategies for Optimizing Venetoclax-Based Treatment for Patients with CLL

EP: 9.Expert Insights for Long-Term Treatment Planning in CLL

EP: 10.Patient with R/R CLL Treated with 2L Venetoclax Therapy

EP: 11.Navigating 2L Treatment Options in CLL

EP: 12.Emerging Data with BTKi Resistance: Expert Insights and Treatment Implications

EP: 13.Management Strategies for BTKi-Related CVAEs in CLL

EP: 14.Updates in CLL Treatment Strategies with Noncovalent BTKis

EP: 15.Looking Ahead: Novel Therapies and Future Perspectives in the Treatment of CLL

Video content above is prompted by the following questions:

How do you select patients for first-line treatment with continuous BTKi therapy? How do available long-term data influence your decision?

Latest Conference Coverage

Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer

Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC

Dr Weiss on the Role of Breast Imaging in Breast Cancer Treatment Decision-Making

Dr Herbst on the Evolution of EGFR Inhibition in Lung Cancer

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512